PRCT · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Inflection · scaling but economically observable
Size is the strategy's, set against its own position and exposure limits.
At $18.38, PRCT requires a 19% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 29%.
The disagreement with the market on this name is about whether demonstrated revenue growth is real — specifically whether the 29.26% TTM figure survives the channel-fill correction — not about the margin path.
The value rests on an exit multiple of 15.0x, a terminal operating margin of 18% and a 8.3% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Aquablation adoption plateaus because per-system utilization stops compounding once the field-inventory tailwind is gone.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market on this name is about whether demonstrated revenue growth is real — specifically whether the 29.26% TTM figure survives the channel-fill correction — not about the margin path. |
| What do we forecast? | Revenue growth of 29% demonstrated; a terminal operating margin of 18%; an exit multiple of 15.0x. |
| What does Street forecast? | Not determined — no consensus figures are on file |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +10.4 percentage points. |
| What is it worth? | Twelve-month target $24.50, +33% from the struck price. Scenario-weighted expected return net of costs +33.3%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| Q2'26 (reporting early August 2026) | The channel-fill-is-flushed limb of the growth thesis | U.S. handpieces sold as a percent of U.S. procedures remains at or above 95% in Q2'26 | U.S. handpieces sold as a percent of U.S. procedures remains below 95% in Q2'26 |
| any two consecutive quarters from Q2'26 | The utilization limb — this is the named impairment cause, tested… | Neither leg of the condition opposite is met at this date | U.S. procedures per installed system declines year on year for two consecutive quarters. FY2025 ran 43.3k procedures… |
| Q2'26 or Q3'26 | The 29.26% demonstrated growth used as the ranking statistic | FY2026 revenue guidance is cut at or above $390m, the low end of the reset range reaffirmed at Q1'26. | FY2026 revenue guidance is cut below $390m, the low end of the reset range reaffirmed at Q1'26. |
| any two consecutive quarters | Gross margin falls below 62% for two consecutive quarters — the… | Gross margin falls at or above 62% for two consecutive quarters | Gross margin falls below 62% for two consecutive quarters |
Aquablation adoption plateaus because per-system utilization stops compounding once the field-inventory tailwind is gone. THAT IS FALSE on the correct denominator. On AVERAGE install base, U.S. procedures per system ran 18.24 / 18.57 / 17.51 / 15.16 (FY24 quarters) then 17.68 / 18.91 / 17.63 / 17.80 (FY25) and 16.45 in Q1'26 -- a decline of 6.9% against Q1'25's 17.68. The named impairment mechanism is ALREADY REGISTERING ONE QUARTER OF YoY DECLINE. The install base grew 42% in FY2025 to 718 U.S. systems and reached 765 at Q1'26 while procedures were flat sequentially at 12.2k, which is the arithmetic of placements outrunning utilization. If that persists, revenue growth converges on install-base growth alone and the company plateaus near $430-460m while still burning cash.
Estimated probability 18%, against the 20% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim on valuation and opportunity cost when forward 12-month expected return falls below the hurdle, which on current estimates occurs at roughly $24.50. On approach to the $24.50 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Aquablation adoption plateaus because per-system utilization stops compounding once the field-inventory tailwind is gone. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Alpha Vantage returned no data; sourced via the web bridge instead. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +10.4 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: aquablation adoption plateaus because per-system utilization stops compounding once the field-inventory tailwind is gone. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $15.04, which forces an immediate review.